Aiming to develop a targeted two-photon PDT for acute myeloid leukemia, Weil et al. described the use of a human serum albumin (HSA)-based platform for selective delivery of the photosensitizer [Ru(bipy)2(NOP)]2+ (NOP = 4-(1H-imidazo [4,5-f] [1,10]phenanthroline-2-yl)-aniline) [132]. The gene discussed is ALB; the disease is acute myeloid leukemia.